INTRODUCTION
Lysosomes contain a variety of acid hydrolases responsible for the degradation of proteins, lipids and carbohydrates that are internalized via endocytosis (Kornfeld and Mellman, 1989) . A large number of genetically determined defects in lysosomal hydrolases are known, manifested either by the absence of a particular hydrolase or by defects in its activity, resulting in accumulation of undegraded substrates, a progressive increase in size and number of lysosomes, and onset of a 'lysosomal storage disease' with its associated clinical manifestations (Neufeld, 1991) .
Defects in the acid hydrolases that degrade sphingolipids are particularly common. The most prevalent lysosomal storage disease, Gaucher disease (Barranger and Ginns, 1989; Grabowski et al., 1990) , results from deficiencies in the activity of glucocerebrosidase (D-glucosyl-N-acylsphingosine glucohydrolase, EC 3.2.1.45; GlcCerase), the enzyme that cleaves the ,3-glucosidic linkage of glucosylceramide (GlcCer) to produce ceramide and glucose. 36 mutations have so far been reported in the GlcCerase gene, including point mutations, insertional mutations, deletions and splicing mutations (Beutler, 1993; Mistry and Cox, 1993; Horowitz and Zimran, 1994) . All of these mutations result in a large, but comparable, decrease in GlcCerase activity when measured in vitro using a variety of synthetic substrates (Hultberg and Ockerman, 1972; Dinur et al., 1984; Osiecki-Newman et al., 1987) . Thus no correlation was observed in vitro between the V.,ax of GlcCerase towards 4-methylumbelliferyl /-D-gluoco- [Futerman and Pagano (1991) Biochem. J. 280, [295] [296] [297] [298] [299] [300] [301] [302] and was hydrolyzed to N- (1-[14C] hexanoyl)-D-erythro-sphingosine ([14C] hexanoyl-Cer) both in vitro and in situ, with an acid pH optimum. A strict correlation was observed between levels of [14C]hexanoyl-GlcCer hydrolysis and Gaucher type in human skin fibroblasts. The mean residual activity measured in vitro for 3 h incubation in type 1 Gaucher fibroblasts (the mild form of the disease) was 46.3 + 4.6 nmol of [14C]hexanoyl-Cer formed per mg protein (n = 9), and in type 2 and 3 fibroblasts (the neuronopathic forms of the disease) was 19.6 + 6.5 (n = 9). A similar correlation was observed when activity was measured in situ, suggesting that the clinical severity of a lysosomal storage disease is related to levels of residual enzyme activity.
pyranoside in different Gaucher alleles [see, for instance, mutations N370S (type 1) and L444P (type 3) in Horowitz and Zimran (1994) ].
In the present study we examined the relationship between levels of residual GlcCerase activity and the type of Gaucher disease. As for all lysosomal storage diseases, Gaucher disease is characterized by marked clinical heterogeneity, varying from a chronic non-neuronopathic type (type 1) to infantile (type 2) and juvenile (type 3) neuronopathic types (Barranger and Ginns, 1989) . However, no correlation has been reported between levels of residual GlcCerase activity measured in vitro and type or genotype (Barranger and Ginns, 1989; Beutler, 1993) . We now use a radioactive short-acyl-chain analogue of glucosylceramide, (Futerman and Pagano, 1991) , to examine this relationship. In contrast with other substrates used for measuring GlcCerase activity, such as 4-methylumbelliferyl 8-D-glucopyranoside (Hultberg and Ockerman, 1972) (Figure 1 ),
[14C]hexanoyl-GlcCer rapidly and spontaneously transfers into biological membranes in the absence of detergent and consequently does not destroy membrane integrity, permitting analysis of enzyme activity in situ in live cells. Radioactive short-acylchain sphingolipid analogues have been used previously to measure the activity of various enzymes of sphingolipid synthesis and degradation both in vitro and in vivo ( Futerman et al., 1990; Pagano, 1991, 1992; Boudker and Futerman, 1993 
I To whom correspondence should be addressed. amino]hexanoyl-D-ervthro-glucosylsphingosine (C6-NBDGlcCer) were synthesized by N-acylation of glucosylsphingosine using the N-hydroxysuccinimide ester of 1 -['4C]hexanoic acid or succinimidyl 6-(7-nitrobenzo-2-oxa-1 ,3-diazol-4-yl)aminohexanoate respectively as described by Pagano (1991,1992) and Schwarzmann and Sandhoff (1987) 
prepared by the same procedure, except that sphingosine was used (Pagano, 1989; Futerman et al., 1990) .
[14C]Hexanoylsphingolipids were prepared as a complex with defatted BSA (molar ratio 1:1) (Boudker and Futerman, 1993) . Stock concentrations of radioactive lipids were determined by liquidscintillation counting in a Packard 1500 Tri-Carb scintillation counter using Lumax/toluene (1:3, v/v) as scintillation fluid.
Cell culture
Human skin fibroblasts from normal donors and patients with Gaucher disease were obtained from the following sources (see Table 1 
Assay of GicCerase activity
In vitro Cells were grown until confluence and then washed three times with Dulbecco's modified Eagle's medium minus Phenol Red. Cells were harvested using a rubber policeman and homogenized in a hand-held Potter-Elvehjem homogenizer in 1 ml of Mes buffer (50 mM, pH 5.5). Homogenates were used either fresh or after storing at -80 'C. In one case, membranes were prepared by centrifugation at 80000 ga. for 10 min at 4 'C. Homogenates (10 ,ug) were incubated with 1 nmol of a [14C]hexanoyl-GlcCerdefatted BSA complex in a final volume of 1 ml of Mes (50 mM, pH 5.5). No other components were added to the reaction mixture. Reactions were allowed to proceed for various times at 37 'C and stopped by addition of 2 ml of chloroform/methanol (1:2, v/v) prior to extraction and analysis of the radioactive lipids (see below).
In situ ['4C]Hexanoyl-GlcCer-BSA complex (1 nmol) was added to the medium (Dulbecco's modified Eagle's medium minus phenol red) of a confluent monolayer of cells for 3 h at 37 'C. Cells were subsequently harvested and homogenized as described above. Aliquots were removed for protein assay (Bradford, 1976) prior to extraction of lipids (see-below). Figure 5 below and Koval and Pagano (1989) (Futerman and Pagano, 1992) . Lipids were recovered from the plates by scraping, and radioactivity was determined by liquid-scintillation counting.
different Gaucher types, with higher activity observed for type 1 Gaucher fibroblasts (the non-neuronopathic type) than for types 2 and 3 (neuronopathic types) as a function of time or protein concentration (Figure 2) Using these standard incubation conditions, a consistent difference was observed in GlcCerase activity between fibroblasts from different Gaucher types (Figure 3) . Residual activity in type 1 fibroblasts varied from 12.0 to 33.1 nmol/mg of protein (Table  1) after 1 h incubation, with a mean value of 20.7 + 6.9 (n = 10), and in type 2 and 3 fibroblasts varied from 3.9 to 12.4 nmol/mg of protein, with a mean value of 8.4 + 2.8 (n = 9). Although some overlap in activity was observed after I h incubation between type 1 and types 2 and 3 fibroblasts (see for instance cell sources 86.4 and IS in Table 1 Prior to these experiments we determined whether short-acylchain analogues of GlcCer were internalized via the endocytic pathway to endosomes and lysosomes in human skin fibroblasts, by using a short-acyl-chain fluorescent derivative of GlcCer, C6-NBD-GlcCer. This fluorescent derivative has been used to study endocytosis in other cell types (Kok et al., 1989 (Kok et al., , 1991 (Kok et al., , 1992 , Cell labelling with short-acyl-chain fluorescent lipid analogues Fibroblasts were grown on 24 mm-diameter glass coverslips and pre-cooled at 7°C for 5 min prior to addition of a C6-NBDG}cCer-defatted BSA complex (5 ,uM). Cells were incubated for 30 min at 7°C, washed three times with Dulbecco's modified Eagle's medium minus Phenol Red, and incubated for a further 3 h at 37°C in Dulbecco's modified Eagle's medium minus Phenol Red. For the first I h of the incubation period, sulforhodamine B (0.1 mg/ml) was present in the incubation medium. C6-NBD-GlcCer-associated fluorescence was subsequently depleted from the plasma membrane by treatment with 80 mM sodium dithionite (Mcintyre and Sleight, 1991) for 5 min at 25°C, and intracellular labelling was monitored by fluorescence microscopy using an Apochromat 63X/1.40 oil objective of an Axiovert 35 microscope, with appropriate filters for NBD or sulforhodamine fluorescence.
RESULTS

In vitro assay of GlcCerase using [14C]hexanoyl-GlcCer
Initial studies were performed to characterize the enzyme activity that hydrolyses [24C] hexanoyl-GlcCer in cell homogenates.
['4C]hexanoyl-GlcCer was hydrolysed by a membrane-associated enzyme with a pH optimum of 5.5 (not shown),-and was completely inhibited by conduritol-,/-epoxide, a specific inhibitor of lysosomal GlcCerase (Legler, 1977) . Activity was dependent on both time (Figure 2a )-and protein concentration (Figure 2b) , and clear differences in enzyme activity were observed between normal and Gaucher fibroblasts. In addition, it was possible to distinguish between residual enzyme activities in cells taken from although some ambiguity has been reported concerning its mode of internalization. In human skin fibroblasts, C6-NBD-GlcCer was internalized to a population of small vesicles (Figure 4 , panel A) that were co-labelled by a fluid-phase marker, sulforhodamine B (Figure 4, panel B) , indicating that C6-NBD-GlcCer can be transported via endosomes to lysosomes, where it is degraded by lysosomal GlcCerase. This was confirmed by biochemical analysis in situ ( Figure 5, lane A) , in which [14C]hexanoyl-GlcCer was degraded to ['4C]hexanoyl-Cer, which was subsequently metabolized in the endoplasmic reticulum/Golgi-apparatus complex (Futerman and Pagano, 1991; Futerman et al., 1990; Koval and Pagano, 1989) Similar to [u4C] hexanoyl-GlcCer hydrolysis in vitro, clear differences in residual enzyme activity were observed in situ between fibroblasts obtained from different Gaucher types. Activity in type 1 fibroblasts varied from 2.9 to 4.5 nmol/mg of protein with a mean value of 3.5 + 0.6 (n = 9), and for type 2 and 3 varied from 0.9 to 2.4 nmol/mg of protein with a mean value of 1.8 +0.5 (n = 10) ( (Pagano and Sleight, 1985; Futerman et al., 1990; Futerman and Pagano, 1992 (Hultberg and Ockerman, 1972; Van Weely et al., 1991) . In such mixtures, the physical state under which the enzymic reaction proceeds is far removed from conditions existing in situ, inasmuch as both substrate and enzyme are present in aqueous solutions as complexes with detergents. In contrast, since short-acyl-chain lipids rapidly transfer into biological (Futerman and Pagano, 1991) and sphingomyelinase activity (Futerman et al., 1990) . In liver fractions, the majority of GlcCerase activity was recovered in a fraction that contained most of a lysosomal marker enzyme (Futerman and Pagano, 1991 (Conzelmann and Sandhoff, 1983/84; Leinekugel et al., 1992) . According to this model, small changes in residual enzyme activity below a critical threshold value would significantly affect the rate of degradation of lysosomal substrates, but changes in levels of enzyme activity above the threshold would have no effect, since the enzyme is present at higher levels than that required to hydrolyse all the substrate. Direct proof of this proposal for Gaucher disease was lacking since no assay was available which permitted accurate analysis of low levels of residual GlcCerase activity. Two recent studies examined whether a correlation exists between residual GlcCerase activity and Gaucher types. In the first (Van Weely et al., 1991), C6-NBD-GlcCer was used as substrate for in situ experiments and no correlation was observed, although incubation times (24 h) were much longer than those used in the current study (3 h), and the amount of C6-NBD-Cer that was metabolized back to C6-NBD-GlcCer was not calculated. In the second study (Agmon et al., 1993) (Furst and Sandhoff, 1992) 
